Johnson & Johnson Innovation-JJDC Inc.

11/20/2026 | Press release | Distributed by Public on 11/20/2026 06:34

JLABS Singapore marks three years of growth, collaboration, and scientific progress

JLABS Singapore marks three years of growth, collaboration, and scientific progress

Since its launch in October 2023, Johnson & Johnson's JLABS Singapore has been committed to supporting emerging life science and healthcare companies as they translate promising science into potential solutions for patients.

The progress of this JLABS community over the last three years reflects the power of collaboration in accelerating healthcare innovation. Today, it has grown to encompass 59 current and alumni member companies that have collectively raised around US$1.16 billion in funding and several have secured partnerships or deals with Johnson & Johnson.

These milestones represent more than numbers. They reflect the ambition of entrepreneurs pursuing solutions to complex healthcare challenges, the partnerships that help move science forward, and the collective commitment to improving health outcomes for patients around the world.

Building a community to advance healthcare innovation

Singapore continues to strengthen its position as a regional hub for biomedical sciences and healthcare innovation, supported by a strong research ecosystem, world-class talent, and a commitment to translating scientific discoveries into real-world applications. New programs, such as A*STAR's AI Drug Discovery (AIDD) program, represent the next wave of innovation for what may become tomorrow's medicines.

Continued collaboration among startups, investors, research institutions, industry, and government will be important in helping navigate the challenges ahead. We extend our heartfelt thanks to our local government collaborator, the Singapore Economic Development Board, for its continued support and collaboration.

By fostering connections across disciplines and geographies, JLABS Singapore aims to remain a valuable part of the ecosystem supporting the next generation of healthcare innovators. For innovators and entrepreneurs developing potentially transformative healthcare solutions, our community offers new opportunities to connect, collaborate, and move science forward.

Innovation in action

Behind every milestone is a team working to solve a difficult problem. The achievements of JLABS Singapore's member companies demonstrate the breadth of scientific ambition across the community and the different paths innovators take as they advance their technologies. Milestones achieved over the past year include:

  • Aevice Health receives approval for the first wearable stethoscope for pediatric use in Australia ( Read here )
  • Aimed Bio advances ADC development with AVIS through AI biomarker research ( Read here )
  • Aimed Bio partners with Sovargen to co-develop AOCs and make a strategic investment ( Read here )
  • Aimed Bio initiates Phase 1 studies of antibody drug conjugate with a global pharma company ( Read here )
  • Bertis establishes a collaboration with Vanderbilt Health for cancer drug discovery ( Read here )
  • Bertis wins a judges' selection at the MSD Health Innovation Summit ( Read here )
  • ChemLex signs an MOU with a global pharma company to drive AI-enabled automated chemistry innovation ( Read here )
  • ChemLex signs RCA with EDDC to accelerate drug discovery and development ( Read here )
  • ChemT named one of Forbes Asia's 100 to Watch companies in 2026 ( Read here )
  • ChemT raises US$5 Million in 18 months to bring AI to Biomanufacturing ( Read here )
  • EverEx obtains MFDS approval for MORA Cure, now being prescribed in Korea ( Read here )
  • NeuroVanda Therapeutics wins ChinaBio's 2026 Startup Spotlight ( Read here )
  • Oncoshot enters service agreement with Japan's Mitsui to collaborate on oncology data services ( Read here )
  • OsseoLabs launches Osscentric with Ramathibodi Hospital ( Read here )
  • QBiotics Group reports positive final efficacy and safety results from its Phase II trial ( Read here )
  • QDX opens its EXESS quantum chemistry engine to academics ( Read here )
  • Reborna Biosciences achieves its second milestone with Kissei ( Read here )
  • Reborna Biosciences achieves First Milestone in Research Collaboration with a pharma company ( Read here)
  • RegCell secures $66 million in additional funding to advance their Nobel-winning scientific discoveries in immune tolerance to the clinic ( Read here )
  • Respiree expands its Series A with ARKRAY and Bizedge Capital ( Read here )
  • Stonewise featured at the forefront of AI-driven drug discovery, with its pipeline advancing into clinical stages ( Read here )
  • VerImmune awarded second place at the RESI JPM 2026 Innovator's Pitch Challenge ( Read here )
  • VerImmune selected for the AI Accelerate 2026 cohort by Microsoft and BLOCK71 Global ( Read here )

Looking ahead: The next chapter

As JLABS Singapore enters its fourth year, the opportunities ahead are significant. Advances across areas such as biotechnology, precision medicine, and AI-enabled research are creating new possibilities for addressing unmet healthcare needs.

"JLABS Singapore has become a vibrant launchpad where bold ideas meet critical support," said Mike Wong, Head of JLABS Singapore. "Our third anniversary is really a celebration of community - of the innovators, investors, partners, and colleagues whose collaboration and resilience have built a supportive ecosystem for early-stage science. Thank you all for making this journey possible. Our next chapter promises to be bright as we continue scaling impact, deepening partnerships, and unlocking new opportunities for health innovation across Singapore and the region."

As the last three years have shown, JLABS Singapore is passionate about our role in bringing entrepreneurial agility together with industry expertise to help innovators navigate the complex journey from scientific discovery to development and commercialization. We look forward to what the next year brings - happy third anniversary, JLABS Singapore!

To learn more about JLABS Singapore and opportunities to join its community, visit JLABS Singapore.

Don't miss a beat & stay connected with JLABS
Subscribe to our Innovation Brief to receive the latest news, highlights, and developments directly in your inbox: https://jnjinnovation.com/subscribe

Johnson & Johnson Innovation-JJDC Inc. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 20, 2026 at 12:35 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]